PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Biocept Inc. (BIOCQ)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

SectorHealthcare
IndustryDiagnostics & Research

Highlights

Year Range$0.00 - $10.50

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Biocept Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Biocept Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2024FebruaryMarchApril
-100.00%
22.02%
BIOCQ (Biocept Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Biocept Inc. had a return of -99.75% year-to-date (YTD) and -100.00% in the last 12 months. Over the past 10 years, Biocept Inc. had an annualized return of -87.68%, while the S&P 500 had an annualized return of 10.46%, indicating that Biocept Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-99.75%5.84%
1 month0.00%-2.98%
6 months-99.97%22.02%
1 year-100.00%24.47%
5 years (annualized)-94.91%11.44%
10 years (annualized)-87.68%10.46%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-99.75%0.00%0.00%
202345.35%-75.20%-80.65%-33.33%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BIOCQ is 54, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of BIOCQ is 5454
Biocept Inc.(BIOCQ)
The Sharpe Ratio Rank of BIOCQ is 4848Sharpe Ratio Rank
The Sortino Ratio Rank of BIOCQ is 100100Sortino Ratio Rank
The Omega Ratio Rank of BIOCQ is 100100Omega Ratio Rank
The Calmar Ratio Rank of BIOCQ is 00Calmar Ratio Rank
The Martin Ratio Rank of BIOCQ is 2121Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Biocept Inc. (BIOCQ) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BIOCQ
Sharpe ratio
The chart of Sharpe ratio for BIOCQ, currently valued at -0.01, compared to the broader market-2.00-1.000.001.002.003.004.00-0.01
Sortino ratio
The chart of Sortino ratio for BIOCQ, currently valued at 84.63, compared to the broader market-4.00-2.000.002.004.006.0084.63
Omega ratio
The chart of Omega ratio for BIOCQ, currently valued at 15.16, compared to the broader market0.501.001.5015.16
Calmar ratio
The chart of Calmar ratio for BIOCQ, currently valued at -1.00, compared to the broader market0.002.004.006.00-1.00
Martin ratio
The chart of Martin ratio for BIOCQ, currently valued at -1.12, compared to the broader market0.0010.0020.0030.00-1.12
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.05, compared to the broader market-2.00-1.000.001.002.003.004.002.05
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.98, compared to the broader market-4.00-2.000.002.004.006.002.98
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.501.001.501.36
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.55, compared to the broader market0.002.004.006.001.55
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.05, compared to the broader market0.0010.0020.0030.008.05

Sharpe Ratio

The current Biocept Inc. Sharpe ratio is -0.01. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.01
2.05
BIOCQ (Biocept Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Biocept Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-100.00%
-3.92%
BIOCQ (Biocept Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Biocept Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biocept Inc. was 100.00%, occurring on Jan 26, 2024. The portfolio has not yet recovered.

The current Biocept Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Feb 19, 20142502Jan 26, 2024
-7.98%Feb 6, 20141Feb 6, 20147Feb 18, 20148

Volatility

Volatility Chart

The current Biocept Inc. volatility is 0.00%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%200.00%400.00%600.00%800.00%1,000.00%NovemberDecember2024FebruaryMarchApril0
3.60%
BIOCQ (Biocept Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Biocept Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items